Literature DB >> 26835698

Syndecan-4 Signaling Is Required for Exercise-Induced Cardiac Hypertrophy.

Jun Xie1, Guixin He1,2, Qinhua Chen1, Jiayin Sun3, Qin Dai1, Jianrong Lu1, Guannan Li1, Han Wu1, Ran Li1, Jianzhou Chen1, Wei Xu1, Biao Xu1.   

Abstract

Cardiac hypertrophy can be broadly classified as either physiological or pathological. Physiological stimuli such as exercise cause adaptive cardiac hypertrophy and normal heart function. Pathological stimuli including hypertension and aortic valvular stenosis cause maladaptive cardiac remodeling and ultimately heart failure. Syndecan-4 (synd4) is a transmembrane proteoglycan identified as being involved in cardiac adaptation after injury, but whether it takes part in physiological cardiac hypertrophy is unclear. We observed upregulation of synd4 in exercise-induced hypertrophic myocardium. To evaluate the role of synd4 in the physiological form of cardiac hypertrophy, mice lacking synd4 (synd4-/-) were exercised by swimming for 4 wks. Ultrasonic cardiogram (UCG) and histological analysis revealed that swimming induced the hypertrophic phenotype but was blunted in synd4-/- compared with wild-type (WT) mice. The swimming-induced activation of Akt, a key molecule in physiological hypertrophy was also more decreased than in WT controls. In cultured cardiomyocytes, synd4 overexpression could induce cell enlargement, protein synthesis and distinct physiological molecular alternation. Akt activation also was observed in synd4-overexpressed cardiomyocytes. Furthermore, inhibition of protein kinase C (PKC) prevented the synd4-induced hypertrophic phenotype and Akt phosphorylation. This study identified an essential role of synd4 in mediation of physiological cardiac hypertrophy.

Entities:  

Year:  2016        PMID: 26835698      PMCID: PMC5004706          DOI: 10.2119/molmed.2015.00026

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  36 in total

Review 1.  Exercise and physical activity: clinical outcomes and applications.

Authors:  Peter Kokkinos; Jonathan Myers
Journal:  Circulation       Date:  2010-10-19       Impact factor: 29.690

Review 2.  Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies.

Authors:  Bianca C Bernardo; Kate L Weeks; Lynette Pretorius; Julie R McMullen
Journal:  Pharmacol Ther       Date:  2010-05-12       Impact factor: 12.310

3.  Syndecan 4 regulation of PDK1-dependent Akt activation.

Authors:  Rong Ju; Michael Simons
Journal:  Cell Signal       Date:  2012-09-10       Impact factor: 4.315

Review 4.  Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure.

Authors:  Julie R McMullen; Garry L Jennings
Journal:  Clin Exp Pharmacol Physiol       Date:  2007-04       Impact factor: 2.557

5.  alpha1G-dependent T-type Ca2+ current antagonizes cardiac hypertrophy through a NOS3-dependent mechanism in mice.

Authors:  Hiroyuki Nakayama; Ilona Bodi; Robert N Correll; Xiongwen Chen; John Lorenz; Steven R Houser; Jeffrey Robbins; Arnold Schwartz; Jeffery D Molkentin
Journal:  J Clin Invest       Date:  2009-11-16       Impact factor: 14.808

6.  NFATc2 is a necessary mediator of calcineurin-dependent cardiac hypertrophy and heart failure.

Authors:  Meriem Bourajjaj; Anne-Sophie Armand; Paula A da Costa Martins; Bart Weijts; Roel van der Nagel; Sylvia Heeneman; Xander H Wehrens; Leon J De Windt
Journal:  J Biol Chem       Date:  2008-05-12       Impact factor: 5.157

7.  Activation or inactivation of cardiac Akt/mTOR signaling diverges physiological from pathological hypertrophy.

Authors:  Ole Johan Kemi; Marcello Ceci; Ulrik Wisloff; Serena Grimaldi; Paolo Gallo; Godfrey L Smith; Gianluigi Condorelli; Oyvind Ellingsen
Journal:  J Cell Physiol       Date:  2008-02       Impact factor: 6.384

Review 8.  Fibroblast-mediated pathways in cardiac hypertrophy.

Authors:  Katsuhito Fujiu; Ryozo Nagai
Journal:  J Mol Cell Cardiol       Date:  2014-01-31       Impact factor: 5.000

9.  Syndecan-4 over-expression preserves cardiac function in a rat model of myocardial infarction.

Authors:  Jun Xie; Jingjing Wang; Ruotian Li; Qin Dai; Yonghong Yong; Bing Zong; Yunxia Xu; Erguang Li; Albert Ferro; Biao Xu
Journal:  J Mol Cell Cardiol       Date:  2012-05-04       Impact factor: 5.000

10.  Interaction of myocardial insulin receptor and IGF receptor signaling in exercise-induced cardiac hypertrophy.

Authors:  Hiroyuki Ikeda; Ichiro Shiojima; Yukako Ozasa; Masashi Yoshida; Martin Holzenberger; C Ronald Kahn; Kenneth Walsh; Takashi Igarashi; E Dale Abel; Issei Komuro
Journal:  J Mol Cell Cardiol       Date:  2009-09-08       Impact factor: 5.000

View more
  3 in total

1.  The female syndecan-4-/- heart has smaller cardiomyocytes, augmented insulin/pSer473-Akt/pSer9-GSK-3β signaling, and lowered SCOP, pThr308-Akt/Akt and GLUT4 levels.

Authors:  Thea Parsberg Støle; Marianne Lunde; Xin Shen; Marita Martinsen; Per Kristian Lunde; Jia Li; Francesca Lockwood; Ivar Sjaastad; William Edward Louch; Jan Magnus Aronsen; Geir Christensen; Cathrine Rein Carlson
Journal:  Front Cell Dev Biol       Date:  2022-08-25

Review 2.  The Role of p38 MAPK in the Development of Diabetic Cardiomyopathy.

Authors:  Shudong Wang; Lijuan Ding; Honglei Ji; Zheng Xu; Quan Liu; Yang Zheng
Journal:  Int J Mol Sci       Date:  2016-06-30       Impact factor: 5.923

3.  Syndecan-4 Is an Independent Predictor of All-Cause as Well as Cardiovascular Mortality in Hemodialysis Patients.

Authors:  Andrzej J Jaroszyński; Anna Jaroszyńska; Stanisław Przywara; Tomasz Zaborowski; Andrzej Książek; Wojciech Dąbrowski
Journal:  PLoS One       Date:  2016-09-29       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.